Compare Salesforce Inc (CRM) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Citius Pharmaceuticals Inc — how do they compare? Salesforce Inc trades at $229.13 (market cap $187.48B), while Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M). The key difference: Salesforce Inc is far larger — about 13765.1× Citius Pharmaceuticals Inc's market cap, and Salesforce Inc pays a 0.77% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Salesforce Inc for 89 Days and Citius Pharmaceuticals Inc for 17 Days on average.
| CRM | CTXR | |
|---|---|---|
Market Cap | $187.48B | $13.62M |
Volume | 6,155,822 | 132,438 |
Sector | Technology | Health |
52-Week High | $266.23 | $1.82 |
52-Week Low | $150.12 | $0.48 |
Typical Hold Time | 89 Days | 17 Days |
Enterprise Value | $217.82B | $3.79M |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $227.80, up 1.44% today, but remains under technical pressure with a bearish signal. The company demonstrates strong fundamentals with consistent earnings beats, 77.28% gross margins, and 21.99% net income margins. Recent AI-driven growth initiatives show promise, with Agentforce and Data 360 ARR reaching $2.9 billion. However, the stock faces headwinds from broader software sector weakness and AI disruption concerns.
The investment case balances strong profitability and AI monetization potential against sector-wide pressures. With 76.5% analyst buy ratings and a $271.91 consensus target offering 19% upside, the stock appears fundamentally undervalued. Key risks include AI competition, macroeconomic sensitivity, and the recent 35% YTD decline testing investor patience despite solid financial performance.
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
